Shares of Nanobiotix S.A. Sponsored ADR (
NASDAQ:NBTX -
Get Free Report) shot up 5.7% during trading on Thursday . The stock traded as high as $10.19 and last traded at $9.89. 8,369 shares changed hands during trading, a decline of 44% from the average session volume of 14,826 shares. The stock had previously closed at $9.35.
Nanobiotix Stock Performance
The firm's 50 day simple moving average is $7.33 and its 200 day simple moving average is $5.01.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Nanobiotix stock. Millennium Management LLC bought a new position in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 13,452 shares of the company's stock, valued at approximately $39,000. Institutional investors and hedge funds own 38.81% of the company's stock.
About Nanobiotix
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
